Jabbour SK, Berman AT, Decker RH, et al. - A nonrandomized controlled trial was conducted to ascertain the safety and tolerability of programmed death ligand-1 (PD-L) inhibition concurrently with definitive chemoradiotherapy for non–small cell lung cancer (NSCLC). Using a 3 plus 3 design, this study was performed between August 30, 2016, and October 24, 2018, with a median follow-up of 16.0 (95% CI, 12.0-22.6) months and data locked on July 25, 2019. A total of 21 individuals were included who had locally advanced, unresectable, stage III NSCLC as determined by multidisciplinary review, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate hematologic, renal, and hepatic function. The outcomes of this research showed that combined treatment with PD-1 inhibitors and chemoradiotherapy for stage III NSCLC is tolerable, with promising PFS of 69.7% at 12 months, and needs future research.